WASHINGTON, DC—In the DanGer Shock trial of Impella CP (Abiomed) in patients with STEMI complicated by cardiogenic shock (STEMI-CS), bleeding occurs not just in the cath lab but also while on ...
WASHINGTON, DC—For patients who present with STEMI complicated by cardiogenic shock (STEMI-CS), it’s not news that the long-awaited DanGer Shock trial showed better 180-day survival after Impella CP ...
Dual antiplatelet therapy remains crucial, with adjustments based on bleeding risk, emphasizing a 12-month duration post-discharge for low-risk patients. The radial artery approach is preferred for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results